Alex Lockhart

Alex Lockhart

Auto-generated profile, based on publicly available information

Alex Lockhart

Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2021 in Cancer
Verified
Journal Article
Open access
PDF file
TPTonia Poteat
Tonia Poteat
MAMary Anne Adams
Mary Anne Adams
JMJowanna Malone
Jowanna Malone
SGSophia Geffen
Sophia Geffen
NGNaomi Greene
Naomi Greene
LDLorraine T. Dean
Lorraine T. Dean
Background: Despite known differences in breast cancer by both race and sexual orientation, data on the intersectional experiences of Black sexual minority women (BSMW) along the care continuum are scant. This study sought to understand delays in breast cancer care by examining the intersection of race and sexual orientation.Methods: This online, cross‐sectional survey enrolled racially and sexually diverse women aged ≥ 35 years who had been diagnosed with breast cancer within the prior 10 years or had an abnormal screening in the prior 24 months. The authors calculated summary statistics by race/sexual orientation categories, and they conducted univariate and multivariable modeling by using multiple imputation for missing data.Results: BSMW (n = 101) had the highest prevalence of care delays with 5.17‐fold increased odds of a care delay in comparison with White heterosexual women (n = 298) in multivariable models. BSMW reported higher intersectional stigma and lower social support than all other groups. In models adjusted for race, sexual orientation, and income, intersectional stigma was associated with a 2.43‐fold increase in care delays, and social support was associated with a 32% decrease in the odds of a care delay.Conclusions: Intersectional stigma may be an important driver of breast cancer inequities for BSMW. Reducing stigma and ensuring access to appropriate social support that addresses known barriers can be an important approach to reducing inequities in the breast cancer care continuum.

1 July 2018 in Sexually Transmitted Diseases
Verified
Journal Article
Open access
ALAlexandre Lockhart
Alexandre Lockhart
MPMatt Psioda
Matt Psioda
JTJie Ting
Jie Ting
SCSara Campbell
Sara Campbell
NMNelly MBChB Mugo
Nelly MBChB Mugo
JSJennifer S. Smith
Jennifer S. Smith
Background: This study aimed to examine the agreement between sexually transmitted infection (STI) screening using self-collected specimens and physician-collected specimens, and to investigate the acceptability of self-collection for screening in an 18-month study of female sex workers in a high-risk, low-resource setting. Methods: A total of 350 female sex workers in Nairobi, Kenya, participated in a prospective study from 2009 to 2011. Women self-collected a cervicovaginal specimen. Next, a physician conducted a pelvic examination to obtain a cervical specimen. Physician- and self-collected specimens were tested for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium (MG) using Aptima nucleic acid amplification assays (Hologic). Specimens were collected at 3-month intervals over 18-month follow-up. κ Statistics measured agreement of positivity between self-collection and physician collection. Results: Baseline STI prevalence was 2.9% for N. gonorrhoeae, 5.2% for C. trachomatis, 9.2% for T. vaginalis, and 20.1% for MG in self-collected samples, and 2.3%, 3.7%, 7.2%, and 12.9%, respectively, in physician-collected samples. κ Agreement was consistently strong (range, 0.66–1.00) for all STIs over the 18-month study period, except for MG, which had moderate agreement (range, 0.50–0.75). Most participants found self-collection easy (94%) and comfortable (89%) at baseline, with responses becoming modestly more favorable over time. Conclusions: Self-collected specimen screening results showed strong agreement to clinical-collected specimens, except for MG, which was consistently detected more commonly in self-collected than in physician-collected specimens. Acceptability of the self-collection procedure was high at baseline and increased modestly over time. In high-risk, low-resource settings, STI screening with self-collected specimens provides a reliable and acceptable alternative to screening with physician-collected specimens.

21 September 2022 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
AWAndrea Walens
Andrea Walens
SASarah C. Van Alsten
Sarah C. Van Alsten
LOLinnea T. Olsson
Linnea T. Olsson
MSMarkia A. Smith
Markia A. Smith
ALAlex Lockhart
Alex Lockhart
MTMelissa A. Troester
Melissa A. Troester
Background: Aberrant expression of DNA repair pathways such as homologous recombination (HR) can lead to DNA repair imbalance, genomic instability, and altered chemotherapy response. DNA repair imbalance may predict prognosis, but variation in DNA repair in diverse cohorts of breast cancer patients is understudied. Methods: To identify RNA-based patterns of DNA repair expression, we performed unsupervised clustering on 51 DNA repair-related genes in the Cancer Genome Atlas Breast Cancer [TCGA BRCA (n = 1,094)] and Carolina Breast Cancer Study [CBCS (n = 1,461)]. Using published DNA-based HR deficiency (HRD) scores (high-HRD ≥ 42) from TCGA, we trained an RNA-based supervised classifier. Unsupervised and supervised HRD classifiers were evaluated in association with demographics, tumor characteristics, and clinical outcomes. Results: : Unsupervised clustering on DNA repair genes identified four clusters of breast tumors, with one group having high expression of HR genes. Approximately 39.7% of CBCS and 29.3% of TCGA breast tumors had this unsupervised high-HRD (U-HRD) profile. A supervised HRD classifier (S-HRD) trained on TCGA had 84% sensitivity and 73% specificity to detect HRD-high samples. Both U-HRD and S-HRD tumors in CBCS had higher frequency of TP53 mutant-like status (45% and 41% enrichment) and basal-like subtype (63% and 58% enrichment). S-HRD high was more common among black patients. Among chemotherapy-treated participants, recurrence was associated with S-HRD high (HR: 2.38, 95% confidence interval = 1.50–3.78). Conclusions: HRD is associated with poor prognosis and enriched in the tumors of black women. Impact: RNA-level indicators of HRD are predictive of breast cancer outcomes in diverse populations.

23 May 2023
Verified
Other
Open access
AWAndrea Walens
Andrea Walens
SASarah C. Van Alsten
Sarah C. Van Alsten
LOLinnea T. Olsson
Linnea T. Olsson
MSMarkia A. Smith
Markia A. Smith
ALAlex Lockhart
Alex Lockhart
MTMelissa A. Troester
Melissa A. Troester
Supplementary Data from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer

23 May 2023
Verified
Other
Open access
PDF file
AWAndrea Walens
Andrea Walens
SASarah C. Van Alsten
Sarah C. Van Alsten
LOLinnea T. Olsson
Linnea T. Olsson
MSMarkia A. Smith
Markia A. Smith
ALAlex Lockhart
Alex Lockhart
MTMelissa A. Troester
Melissa A. Troester
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer

23 May 2023
Verified
Other
Open access
AWAndrea Walens
Andrea Walens
SASarah C. Van Alsten
Sarah C. Van Alsten
LOLinnea T. Olsson
Linnea T. Olsson
MSMarkia A. Smith
Markia A. Smith
ALAlex Lockhart
Alex Lockhart
MTMelissa A. Troester
Melissa A. Troester
Background:Aberrant expression of DNA repair pathways such as homologous recombination (HR) can lead to DNA repair imbalance, genomic instability, and altered chemotherapy response. DNA repair imbalance may predict prognosis, but variation in DNA repair in diverse cohorts of breast cancer patients is understudied.Methods:To identify RNA-based patterns of DNA repair expression, we performed unsupervised clustering on 51 DNA repair-related genes in the Cancer Genome Atlas Breast Cancer [TCGA BRCA (n = 1,094)] and Carolina Breast Cancer Study [CBCS (n = 1,461)]. Using published DNA-based HR deficiency (HRD) scores (high-HRD ≥ 42) from TCGA, we trained an RNA-based supervised classifier. Unsupervised and supervised HRD classifiers were evaluated in association with demographics, tumor characteristics, and clinical outcomes.Results: Unsupervised clustering on DNA repair genes identified four clusters of breast tumors, with one group having high expression of HR genes. Approximately 39.7% of CBCS and 29.3% of TCGA breast tumors had this unsupervised high-HRD (U-HRD) profile. A supervised HRD classifier (S-HRD) trained on TCGA had 84% sensitivity and 73% specificity to detect HRD-high samples. Both U-HRD and S-HRD tumors in CBCS had higher frequency of TP53 mutant-like status (45% and 41% enrichment) and basal-like subtype (63% and 58% enrichment). S-HRD high was more common among black patients. Among chemotherapy-treated participants, recurrence was associated with S-HRD high (HR: 2.38, 95% confidence interval = 1.50–3.78).Conclusions:HRD is associated with poor prognosis and enriched in the tumors of black women.Impact:RNA-level indicators of HRD are predictive of breast cancer outcomes in diverse populations.